BR9807675A - Processos para fabricação de um complexo argimina-silicato-inositol, para prevenir ou inibir a arterioesclerose em um indivìduo, para suplementação dietética de arginina, para prevenção da desmineralização de ossos ou degradação de cartilagens em um indivìduo com necessidade do mesmo, para tratamento de um mamìfero para aliviar os efeitos patológicos da osteoporose, osteogenesis imperfecta, fraturas ósseas, osteoartrites e outras doenças de ossos e cartilagens, complexo arginina-silicato-inositol, uso do mesmo, e formulação farmacêutica opositora da desmineralização óssea e inibidora da degradação de cartilagem - Google Patents

Processos para fabricação de um complexo argimina-silicato-inositol, para prevenir ou inibir a arterioesclerose em um indivìduo, para suplementação dietética de arginina, para prevenção da desmineralização de ossos ou degradação de cartilagens em um indivìduo com necessidade do mesmo, para tratamento de um mamìfero para aliviar os efeitos patológicos da osteoporose, osteogenesis imperfecta, fraturas ósseas, osteoartrites e outras doenças de ossos e cartilagens, complexo arginina-silicato-inositol, uso do mesmo, e formulação farmacêutica opositora da desmineralização óssea e inibidora da degradação de cartilagem

Info

Publication number
BR9807675A
BR9807675A BR9807675-2A BR9807675A BR9807675A BR 9807675 A BR9807675 A BR 9807675A BR 9807675 A BR9807675 A BR 9807675A BR 9807675 A BR9807675 A BR 9807675A
Authority
BR
Brazil
Prior art keywords
silicate
arginine
individual
cartilage
complex
Prior art date
Application number
BR9807675-2A
Other languages
English (en)
Portuguese (pt)
Inventor
Mark Mccarty
Jan Zielinski
Original Assignee
Nutrition 21
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nutrition 21 filed Critical Nutrition 21
Publication of BR9807675A publication Critical patent/BR9807675A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/695—Silicon compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/04—Esters of silicic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Silicates, Zeolites, And Molecular Sieves (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
BR9807675-2A 1997-02-12 1998-02-11 Processos para fabricação de um complexo argimina-silicato-inositol, para prevenir ou inibir a arterioesclerose em um indivìduo, para suplementação dietética de arginina, para prevenção da desmineralização de ossos ou degradação de cartilagens em um indivìduo com necessidade do mesmo, para tratamento de um mamìfero para aliviar os efeitos patológicos da osteoporose, osteogenesis imperfecta, fraturas ósseas, osteoartrites e outras doenças de ossos e cartilagens, complexo arginina-silicato-inositol, uso do mesmo, e formulação farmacêutica opositora da desmineralização óssea e inibidora da degradação de cartilagem BR9807675A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/799,784 US5707970A (en) 1997-02-12 1997-02-12 Arginine silicate complex and use thereof
PCT/US1998/002443 WO1998034647A1 (en) 1997-02-12 1998-02-11 Arginine silicate inositol complex and use thereof

Publications (1)

Publication Number Publication Date
BR9807675A true BR9807675A (pt) 2000-02-15

Family

ID=25176739

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9807675-2A BR9807675A (pt) 1997-02-12 1998-02-11 Processos para fabricação de um complexo argimina-silicato-inositol, para prevenir ou inibir a arterioesclerose em um indivìduo, para suplementação dietética de arginina, para prevenção da desmineralização de ossos ou degradação de cartilagens em um indivìduo com necessidade do mesmo, para tratamento de um mamìfero para aliviar os efeitos patológicos da osteoporose, osteogenesis imperfecta, fraturas ósseas, osteoartrites e outras doenças de ossos e cartilagens, complexo arginina-silicato-inositol, uso do mesmo, e formulação farmacêutica opositora da desmineralização óssea e inibidora da degradação de cartilagem

Country Status (16)

Country Link
US (3) US5707970A (cg-RX-API-DMAC10.html)
EP (1) EP1007096B1 (cg-RX-API-DMAC10.html)
JP (1) JP2001512443A (cg-RX-API-DMAC10.html)
KR (1) KR20000070977A (cg-RX-API-DMAC10.html)
CN (1) CN1182873C (cg-RX-API-DMAC10.html)
AT (1) ATE251914T1 (cg-RX-API-DMAC10.html)
AU (1) AU722975B2 (cg-RX-API-DMAC10.html)
BR (1) BR9807675A (cg-RX-API-DMAC10.html)
CA (1) CA2279233A1 (cg-RX-API-DMAC10.html)
DE (1) DE69819016T2 (cg-RX-API-DMAC10.html)
DK (1) DK1007096T3 (cg-RX-API-DMAC10.html)
ES (1) ES2209112T3 (cg-RX-API-DMAC10.html)
HU (1) HUP0001998A3 (cg-RX-API-DMAC10.html)
IL (1) IL130925A0 (cg-RX-API-DMAC10.html)
PT (1) PT1007096E (cg-RX-API-DMAC10.html)
WO (1) WO1998034647A1 (cg-RX-API-DMAC10.html)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5707970A (en) 1997-02-12 1998-01-13 Nutrition 21 Arginine silicate complex and use thereof
US20020068365A1 (en) * 1998-07-28 2002-06-06 Eric H. Kuhrts Controlled release nitric oxide producing agents
AU2001281337A1 (en) * 2000-07-24 2002-02-05 Nutrition 21, Inc. Arginine saccharate and use thereof
US6552074B2 (en) * 2000-11-16 2003-04-22 Fukumi Morishige Arginine/ascorbic acid mixed powder as an oral supplement
TWI300947B (en) * 2001-07-12 2008-09-11 Semiconductor Energy Lab Display device using electron source elements and method of driving same
AU2002360765C1 (en) * 2001-12-20 2009-06-11 Trivascular, Inc. Advanced endovascular graft
US7147661B2 (en) * 2001-12-20 2006-12-12 Boston Scientific Santa Rosa Corp. Radially expandable stent
US20040097467A1 (en) * 2002-08-22 2004-05-20 Vijaya Juturu Arginine silicate inositol complex and use thereof
US6803456B1 (en) * 2003-08-13 2004-10-12 Rutherford Chemicals Llc Process for the production of arginine-silicate complex
US7803178B2 (en) * 2004-01-30 2010-09-28 Trivascular, Inc. Inflatable porous implants and methods for drug delivery
CA2558573A1 (en) * 2004-03-11 2005-09-22 Trivascular, Inc. Modular endovascular graft
ES2323141T3 (es) * 2004-08-12 2009-07-07 Quest Pharmaceutical Services Composiciones farmaceuticas para el suministro por liberacion controlada de compuestos biologicamente activos.
US7919620B2 (en) * 2005-06-01 2011-04-05 Coral Biotech Kabushiki Kaisha Agent for suppressing blood pressure elevation
ITMI20060677A1 (it) * 2006-04-06 2007-10-07 Damor Farmaceutici Profarmaci dell'arginina ad elevata attivita'terapeutica
CN101573127B (zh) * 2006-09-21 2013-04-10 大黑俊树 硬组织再生促进剂
ES2579229T3 (es) 2007-03-13 2016-08-08 Jds Therapeutics, Llc Procedimientos y composiciones para la liberación sostenida de cromo
WO2009002867A2 (en) 2007-06-26 2008-12-31 Nutrition 21, Inc. Multiple unit dosage form having a therapeutic agents in combination with a nutritional supplement
GB0805279D0 (en) * 2008-03-20 2008-04-30 Univ Nottingham Trent Food supplement
WO2012035364A1 (en) 2010-09-15 2012-03-22 Creogen D.O.O. Stabilized solution of ortho-silicic acid, its preparation and use
AU2012223282B2 (en) 2011-03-01 2017-02-02 Nutrition 21, Llc Compositions of insulin and chromium for the treatment and prevention of diabetes, hypoglycemia and related disorders
US11191735B2 (en) 2015-03-13 2021-12-07 Nutrition 21, Llc Arginine silicate for periodontal disease
US20170000809A1 (en) * 2015-06-30 2017-01-05 Jds Therapeutics, Llc Arginine silicate inositol for improving cognitive function
CN107835778B (zh) 2015-07-13 2020-06-09 奥的斯电梯公司 阻遏装置抑制钥匙
US20170135969A1 (en) 2015-11-12 2017-05-18 Jds Therapeutics, Llc Topical arginine-silicate-inositol for wound healing
AU2017217466A1 (en) 2016-02-11 2018-08-23 Nutrition 21, Llc Chromium containing compositions for improving health and fitness
GB2568849B (en) 2016-09-01 2022-08-10 Nutrition 21 Llc Magnesium biotinate compositions and methods of use
CN113329680A (zh) 2018-11-02 2021-08-31 营养21有限责任公司 用于改善视频游戏者认知功能的含有肌醇稳定的精氨酸硅酸盐复合物和肌醇的组合物
GB2613672A (en) 2019-12-16 2023-06-14 Nutrition 21 Llc Methods of production of aginine-silicate complexes
CA3237984A1 (en) * 2021-11-12 2023-05-19 Nutrition21, LLC Compositions and methods for treating or preventing myopathy in poultry
CN118206406B (zh) * 2024-03-20 2025-08-15 山东农业大学 精氨酸硅酸盐肌醇络合物在提高作物果实品质中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3337403A (en) * 1963-09-05 1967-08-22 Hoffmann La Roche Stable and palatable pharmaceutical compositions
US4297349A (en) * 1980-04-15 1981-10-27 Sandoz, Inc. Silicon-bearing carboxylic acids and amides
US4385052A (en) * 1981-07-20 1983-05-24 International Plant Research Institute, Inc. Use of trialkylsilyl-6-aminonicotinamides for the treatment of psoriasis
FR2610522B1 (fr) * 1987-02-06 1989-08-18 Gueyne Jean Produit therapeutique a base de derives organiques du silicium
US5250569A (en) * 1991-04-22 1993-10-05 Godfrey Science & Design, Inc. Amino acid flavorings of aluminum astringent for oral use
US5622980A (en) * 1993-08-17 1997-04-22 Applied Analytical Industries, Inc. Oral compositions of H2-antagonists
FR2745498A1 (fr) * 1996-02-29 1997-09-05 Giroux Jean Marc Composition pur augmenter conjointement la tolerance biologique et l'efficacite amincissante des produits hyperproteines hypocaloriques destines au traitement de l'obesite
US5707970A (en) * 1997-02-12 1998-01-13 Nutrition 21 Arginine silicate complex and use thereof

Also Published As

Publication number Publication date
JP2001512443A (ja) 2001-08-21
WO1998034647A1 (en) 1998-08-13
US6156735A (en) 2000-12-05
DE69819016D1 (de) 2003-11-20
ATE251914T1 (de) 2003-11-15
CN1182873C (zh) 2005-01-05
HUP0001998A2 (hu) 2000-10-28
EP1007096A1 (en) 2000-06-14
US6344444B1 (en) 2002-02-05
PT1007096E (pt) 2004-03-31
DE69819016T2 (de) 2004-04-29
ES2209112T3 (es) 2004-06-16
HUP0001998A3 (en) 2002-01-28
US5707970A (en) 1998-01-13
EP1007096B1 (en) 2003-10-15
DK1007096T3 (da) 2003-12-01
IL130925A0 (en) 2001-01-28
CA2279233A1 (en) 1998-08-13
AU6273798A (en) 1998-08-26
AU722975B2 (en) 2000-08-17
CN1246801A (zh) 2000-03-08
KR20000070977A (ko) 2000-11-25

Similar Documents

Publication Publication Date Title
US6887497B2 (en) Composition for the treatment and prevention of osteoarthritis, rheumatoid arthritis and improved joint function
Aaseth et al. Fluoride: a toxic or therapeutic agent in the treatment of osteoporosis?
BR9911020A (pt) Novas composições farmacêuticas para tratamento e salvamento, e método para a sua preparação
BR9815442A (pt) Liberação terapêutica dirigida de compostos de vitamina d
RS20060150A (sr) Preparat i postupak za olakšavanje zarastanja kosti
CN104188999A (zh) 一种具有增加骨密度、改善骨骼及关节功能的组合物及其制备方法
Chines et al. Antacid and sucralfate-induced hypophosphatemic osteomalacia: a case report and review of the literature
CA2730009C (en) Topical medicament
SE9001308D0 (sv) Foerfarande foer att behandla och foerebygga foertvining av bensubstans
ATE413863T1 (de) Sprudelnde pharmazeutische zusammensetzungen mit vitamin d, calcium und phospat und ihre therapeutische verwendung
US20250213644A1 (en) Compositions and methods for treatment of bone-related disease or disorder
EP3010496B1 (en) Arginine for use in the treatment and/or prevention of osteoarthritis
Venkatesan et al. Osteoporosis treatment: Marine algal compounds
Boivin et al. Fluoride and osteoporosis
Martini et al. Bilateral atraumatic avulsion fracture of the calcaneal tubercle in osteomalacia during fluoride therapy-a case report
Gudmundson et al. Does diphenylhydantoin accelerate healing of fractures in mice?
BR0210975A (pt) Composição oral para uso como um agente profilático, terapêutico e/ou cosmético para a obesidade/excesso de peso em mamìferos não diabéticos, inclusive em seres humanos e preparação de uma composição oral
ES2151486T3 (es) Composiciones farmaceuticas que contienen complejos de 3-hidroxi-4-pironas.
RU2710599C2 (ru) Средство и способ коррекции нарушений структуры костной ткани, вызванных длительным употреблением глюкокортикоидов
RU2327478C1 (ru) Композиция, стимулирующая регенерацию опорных тканей (варианты)
CN1322888C (zh) 一种治疗骨质疏松的药物的用途
Ashok et al. Role of Nutraceuticals in the Treatment of Degenerative Osteoporosis or Disc Disease
Weil et al. Treatment of fourth metatarsal base fracture non-unions in middle aged women with osteoporosis: a case study
Melick et al. Use of porcine calcitonin in osteoporosis
Dequeker et al. Prevention of postmenopausal bone loss by 1α vitamin D3

Legal Events

Date Code Title Description
B04C Request for examination: application reinstated [chapter 4.3 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements